Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Health Companies Inc BHC


Primary Symbol: T.BHC

Healthcare
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures and markets, primarily in the therapeutic areas of gastroenterology (GI), hepatology, neurology and dermatology, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with... see more

Recent & Breaking News (TSX:BHC)

Bausch Health Agrees To Sell Amoun Pharmaceuticals

PR Newswire March 31, 2021

Salix Launches GastroHub for Advanced Practice Providers, an Educational Website Designed To Provide Nurse Practitioners and Physician Assistants With Relevant Information for Treating IBS-D and HE

Canada NewsWire March 30, 2021

Bausch Health Announces CFO Succession Plan

Canada NewsWire March 11, 2021

Bausch Health Publishes Pipeline Update For The Barclays Global Healthcare Conference

PR Newswire March 9, 2021

Solta Medical Announces the U.S. Launch of The Clear + Brilliant® Touch Laser

Canada NewsWire March 8, 2021

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

Canada NewsWire February 26, 2021

Bausch Health Companies Inc. Announces Fourth-Quarter And Full-Year 2020 Results And Provides 2021 Guidance

Canada NewsWire February 24, 2021

Bausch Health Announces Agreement With Carl C. Icahn

Canada NewsWire February 24, 2021

Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops

PR Newswire February 23, 2021

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

Canada NewsWire February 22, 2021

Salix Announces 2021 Gastrointestinal Health Scholars Program

Canada NewsWire February 18, 2021

Bausch Health Announces Participation In Upcoming Investor Conferences

PR Newswire February 16, 2021

Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP

Canada NewsWire February 11, 2021

Clearside Biomedical Featured in Multiple Data Presentations at the 44th Virtual Annual Macula Society Meeting

GlobeNewswire February 8, 2021

Ortho Dermatologics Announces 2021 Aspire Higher Scholarship Program

Canada NewsWire February 2, 2021

Prevent Blindness and Bausch + Lomb to Launch Year-Long Video Series to Raise Awareness of Age-Related Macular Degeneration (AMD)

PR Newswire February 1, 2021

Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24

PR Newswire January 27, 2021

South Korea's MFDS Approves LUMIFY® Eye Drops

PR Newswire January 21, 2021

Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE(TM) Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium

Canada NewsWire January 20, 2021

Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (perfluorohexyloctane)

PR Newswire January 19, 2021